Acutaas Chemicals Ltd

Acutaas Chemicals Ltd

3,944.00
INR
-3.30
(-0.08%)
53.36EPS
61.13P/E
268.49BMarket Cap
Feb 14Next Earn

Q2 FY2027 · Earnings Call TranscriptOctober 27, 2026

Operator

Ladies and gentlemen, good day, and welcome to Aequitas Limited Q2 FY '27 earnings conference call, hosted by Equirus Securities Private Limited. As a reminder, all participant lines will be in the listen-only mode, and there will be an opportunity for you to ask questions after the presentation concludes.

Should you need assistance during the conference call, please signal an operator by pressing star then zero on your touch-tone phone. Please note that this conference is being recorded.

I now hand the conference over to Mr. Siddharth Gadekar from Equirus Securities Private Limited.

Thank you, and over to you, sir.

Siddharth Gadekar

Good evening, everyone, and thank you for joining us on Aequitas Chemicals' 2Q FY '27 earnings conference call. Today, we have with us Aequitas Chemicals management, represented by Mr.

Naresh Patel, Chairman and Managing Director; Mr. Abhishek Patel, Vice President, Strategy; and Mr.

Bhavin Shah, Chief Financial Officer. I would now like to invite Mr.

Bhavin Shah to initiate the proceedings. Over to you, sir.

Thank you.

Bhavin Shah

Thank you, Siddharth. Good evening, everyone.

We are pleased to welcome you all to our earnings conference call to discuss Q2 and H1 FY '27 financials. Please note that a copy of our disclosure is available on the Investors section of our website as well as on the stock exchanges.

Please do note that anything said on this call which reflects our outlook towards the future or which could be construed as forward-looking statements must be reviewed in conjunction with the risks that the company may faces. The conference call is being recorded, and the transcript along with the audio of the same will be made available on the website of the company and exchanges.

Please also note that the audio of the conference call is the copyright material of Aequitas Chemicals and cannot be copied, rebroadcasted, or attributed in press or media without specific and written consent of the company. Now, I would like to hand over the floor to our CMD, Mr.

Naresh Patel, for his opening statement. Over to you, sir.

Naresh Patel

Thank you, Bhavin. Good evening, everyone.

I hope you are all doing well. With Diwali just around the corner, I would like to extend warm wishes from the Aequitas family to you and your loved ones.

May this festive season bring joy, prosperity, good health, and success to everyone. Wishing you and your family a very Happy Diwali.

I will start my remarks with pharmaceutical intermediate business. Demand environment remains robust, and whatever cost pressure we faced due to geopolitical issues, we have been able to pass them on successfully.

On the generic side, several large products are going off-patent. We have already developed intermediates for those products long back.

Therefore, we are benefiting from our strategy of developing products ahead of the market. Coming to CDMO, during our Q3 FY '25 earnings call in January 2025, we had shared our ambition of achieving ₹1,000 crore in CDMO revenue by FY '28.

Based on the current orders of existing as well as new CDMO contracts, we now believe we will achieve this target one year ahead of schedule. It means in FY '27, we will be achieving this ₹1,000 crore.

Here, I would like to highlight that we continue to add very exciting products to our CDMO pipeline. A couple of these products we have potentially to become billion-dollar product for our innovator customers.

Here, I would like to say that this CDMO business will be double in next three financial years, it means from ₹1,000 crore to achieve new target we had set as ₹2,000 crore by FY 2030. Now, let me move to specialty chemicals.

Starting with battery chemicals, from industry point of view, demand continues to exceed supply. I am happy to share that this was our first quarter of commercial revenue from battery chemicals business.

Initial commercial shipment of our third product were dispatched during last quarter. We will see a scale-up of third product in coming quarters.

We have also sent pilot-scale validation batches of fourth product to the customers. Overall, the start is very encouraging, and I believe we will see a very strong ramp-up as we already have orders in our hand.

Coming to semiconductor chemicals, I'm happy to share that we have inaugurated our plant in South Korea ahead of schedule. This state-of-the-art facility will manufacture chemicals that goes into photoresists, packaging material, etching materials, and other semiconductor applications.

We have been submitting multiple qualification batches to customers in South Korea, which showcased strong customer traction. I believe FY '28 will be year of ramp-up for initial products, while we will continue to add more products into the basket.

Moving to BFC, BFC is seeing strong order demand from its US customer, as well as we have started receiving orders from Korean and Japanese customers. During the last quarter, our US customer was acquired by another US-based company.

This caused a temporary pause in the shipments. Supplies have now resumed, and operations are back to normal.

On commodity chemicals, phasing out of old product is going on as per plan, and that is visible in our numbers as well. Turning to our performance for the quarter, we delivered strong revenue of ₹4,369 million, which is growth of 42.7% year-on-year.

This was driven by strong performance of our pharmaceutical intermediate business, whereas specialty chemicals business was muted during the quarter. Before I conclude, I would also like to revise our revenue growth guidance for current year from 25% to around 30%.

We are also raising our EBITDA margin guidance to 38% to 40% between 38% to 40% range for FY '27. With that, I would now like to hand over to our Vice President of Strategy, Abhishek Patel, who will walk you through the detail business updates.

Abhishek Patel

Thank you, Naresh. Good evening, everyone.

Let me share some additional insights into our business performance for the quarter. Starting with advanced pharmaceutical intermediate segment.

This segment delivered robust performance with revenue of ₹4,020 million in Q2 FY '27, reflecting a strong year-on-year growth of 53.1%. CDMO business continued its strong growth trajectory, supported by robust growth in core pharmaceutical business.

We are happy to share that we delivered more than 25% year-on-year growth in our core business this quarter, driven by ramp-up of new products as well as strong growth in top products. We are happy to share that we have received order for new CDMO contracts, which are expected to start contributing revenue from H2 FY '27.

Moving on to specialty chemical segment. The revenue of quarter was ₹349 million, ₹349 million, which is down 20% YoY, driven by phasing out of old commodity products as well as temporary pause in shipment in BFC business due to ownership change of the US customer, as highlighted by Naresh.

I am happy to share the shipments have started, and we are very much on target to deliver a growth in BFC this year. Now turning to the capex, capex for H1 FY '27 was ₹1,239 million.

It is spread across electrolyte additive project, pilot plant, Indicam site, and maintenance capex. Furthermore, for the full year, we believe our total capex would be around ₹3,000 million.

In H2 FY '27, we plan to do additional capex of ₹1,650 million capex, which will have around ₹1,000 million for electronic-grade chemicals, ₹450 million for second phase of electrolyte additive capex, and remaining will be for the maintenance capex. Please note, this calculation does not include planned R&D capex as well as the land acquisition.

With that, I will now hand over our floor to our Chief Financial Officer, Bhavin Shah, who will walk you through details related to financials. Over to you, Bhavin.

Bhavin Shah

Thank you, Abhishek. I would like to briefly highlight the key performance metrics for the quarter and half year before we open the floor for questions.

Let me start with quarterly performance. Revenue from operations for the quarter reached ₹4,369 million, representing 42.7% growth YoY.

Gross profit for the quarter was ₹2,715 million, reflecting 59% increase compared to the same period last year. The gross margin expanded by 637 basis points YoY to 62.1%.

Gross margin was driven by higher contribution from pharma intermediate business compared to the same period last year. EBITDA for the quarter was ₹1,760 million, up 84.6% YoY.

EBITDA margins were at 40.3%, up 914 basis points YoY. EBITDA margin was driven by expansion in gross margin as well as operating leverage.

PAT for the quarter was ₹1,231 million, up 71.4% YoY. PAT margins for the quarter were at 28.2%, which show an expansion of 472 basis points YoY.

Moving on to the half-yearly numbers. Revenue from operations for H1 FY '27 was ₹7,666 million, representing 49.3% growth YoY.

EBITDA for H1 FY '27 was ₹2,890 million, up 97.7% YoY. EBITDA margins were at 37.7%, up 922 basis points YoY.

PAT for the first half FY '27 was ₹1,981 million, up 71% YoY. PAT margins for H1 FY '27 were at 25.8%, which show an expansion of 328 basis points YoY.

Moving to the balance sheet item, net cash and cash equivalents were around ₹3,009 million as on 30th September 2026. Our working capital for the quarter stands at 115 days vis-a-vis 99 days in Q1 FY '27.

This was driven by higher debtor days. With that, I request the moderator to open the floor for questions.

Thank you.

Operator

Thank you very much. We will now begin the question-and-answer session.

Anyone who wishes to ask a question may press star and one on the touch-tone telephone. If you wish to remove yourself from the question queue, you may press star and two.

Participants are requested to use handsets while asking a question. Ladies and gentlemen, we will wait for a moment while the question queue assembles.

The first question comes from the line of Abhijit from KIE. Please go ahead.

Abhijit Akella

Good afternoon. Thank you so much, and congratulations on the very strong results.

Just on the new CDMO products that you mentioned, which will begin contributing in 2H, any sense you could give us on the revenues that we should expect in this financial year itself? Then when we are speaking about this target of doubling CDMO revenues in the next three years, how much would be the contribution of these newer products within that target?

Abhishek Patel

I'm afraid that I'll not be able to share the product-wise revenue guidance. That's the reason we are saying that we are very much confident to close this year with ₹1,000 crore revenue in CDMO segment because we have already got some good orders for the some of the products which were already validated a few quarters back, and now we are getting the orders.

We see a very good new business opportunity in this new CDMO, as well as the some of the CDMO pipeline, which we are expecting to get a good revenue generation in coming quarters and years. That's the reason we are giving that 1,000, ₹2,000 crore kind of guidance for next three years.

I'm afraid I will not be able to share the any product-wise revenue bifurcation.

Abhijit Akella

Got it. Just, maybe the number of products that you have that are getting commercialized this year, could you talk about that?

Abhishek Patel

There are multiple products. As we said, the four products were already kind of validated few quarters back, and there are additional products which are getting commercialized this year.

There are eight to nine products in total, you can say, that those are getting into revenue stream in next one, 1.5 year time.

Abhijit Akella

Understood. The other one I just had was on the specialty chemicals side.

Of the key growth projects you have there: battery chemicals, semiconductor chemicals, and now this electronic grade, could you please help us with the timeline for commencement of revenues from each of these, and what sort of trajectory we should expect from each of these?

Abhishek Patel

As we said last time, that now we are phasing out some of our old legacy product related to parabens and MS, and there those are getting replaced with some better margin and a futuristic product. In that context only, we have announced the capex related to bulk electronic-grade chemical manufacturing.

As we just announced the capex, it will take 1.5-year time to get the capex to get completed. Maybe by H1 FY '29, we should be starting the production.

Meanwhile, the battery products have already started contributing in the revenue pie, and that's an encouraging signal for our specialty chemical business side.

Abhijit Akella

Got it. Thank you so much, and I'll get back in the queue for any more.

Abhishek Patel

Sure. Thank you.

Operator

Thank you. Participants who wish to ask a question may press star and one on their touch-tone telephone.

The next question comes from the line of Aditya Iyer from HDFC Securities. Please go ahead.

Aditya Iyer

Hi, am I audible?

Operator

Yes, sir.

Abhishek Patel

Yes.

Aditya Iyer

Congratulations on a great set of numbers. For the existing CDMO business, what kind of traction are we seeing for darolutamide in terms of product adoption?

What kind of revenue potential do we expect from this molecule in the near future?

Abhishek Patel

For darolutamide, we are not in position to comment anything about that product because it's not our product. It's a innovator-driven product, and that is very much very well-covered in the market.

For that, I think it's better you refer all those already available public market information. What we are saying that based on the customer's requirement of that particular product as well as the other customer, based on that, we are guiding that our CDMO revenue should get doubled in next three years' time.

Aditya Iyer

Okay. For our Ankleshwar unit, what is the total amount that we've invested and the utilization as of H1 FY '27?

Abhishek Patel

For Ankleshwar unit, we have invested ₹330 crore. Utilization level for Q2 FY '27 was 30%.

Aditya Iyer

By FY '28, we are expecting peak utilization? Roughly.

Abhishek Patel

Yes. It should largely get filled up by FY '28.

Aditya Iyer

In this electronic-grade chemicals, when we say, do we mean battery-grade or semiconductor-grade chemicals?

Abhishek Patel

Both. It will be kind of trajectory will move forward for various grades.

Aditya Iyer

Okay. So, 50 1:1 mix or what is it?

Abhishek Patel

Sorry? Meaning,

Aditya Iyer

is it 50-50 battery, semiconductor grade, or what is the proportion?

Abhishek Patel

No, as of now we are only going with the electronic-grade chemicals. Going forward, we'll have a additional plan.

It will be starting with the electronic-grade chemical only.

Aditya Iyer

Okay. Thank you so much.

That's it from my end.

Operator

Thank you. The next question comes from the line of Mr.

Siddharth Gadekar from Equirus Securities Private Limited. Please go ahead.

Siddharth Gadekar

Hi sir. The first question on our electrolyte business, when we historically spoke about this business, the realizations for these products were closer to $10, $12, but in the last six, seven months, if we look at the prices, they have moved up to $35, $30, $35-plus.

How should we think about this business going ahead in terms of realization and margins? We were

Abhishek Patel

right from beginning, we are saying that we have already signed long-term supply contract all in place, and based on that contract, we get the revised pricing based on the some of the key raw material price movement as well as the exchange rate fluctuation. We are not riding on those some of the waves wherein price fluctuation we don't want to get benefit from those price fluctuation or when it gets down, we get down.

It is more of a we look into our plate, and we get our good profit, wherein we get a timely payback of our investment, and then look for a newer project. This how what the policy philosophy what we are following.

Siddharth Gadekar

Okay. Sir, when from a modeling perspective, when we look at the revenue potential from these projects, should we assume a asset turnover, or they would be more closer to spot prices, given that raw material prices also could be volatile?

Abhishek Patel

No, for the understanding of your thing, as it was near to kind of double-digit kind of dollar value, there will be additional some of the realization because of price movement, but it will not be kind of $30, $35 kind of pricing. It can be early teens kind of pricing scenario.

Siddharth Gadekar

Okay. Second question on the electronic chemical business, given that it seems like a 2x asset turnover, where your realizations are closer to $1, $1.5, can you give some sense on what kind of product this is and what would be the major end applications and it would be more like a commodity chemical or a niche molecule in this space?

Abhishek Patel

First thing, we are not saying it is kind of 2x kind of asset turn. It will be three at least 3x kind of asset turn we are expecting there.

We have not commented anything on the realization side. What we are saying that, it will be a kind of bulk electronic chemical and solvent products.

Siddharth Gadekar

Got it. Sir, and the timelines for this still remains FY '29?

Abhishek Patel

Yes, first half of FY '29. It will take around 1.5 years to get completed in capex.

Siddharth Gadekar

Sir, and the last question is on the CDMO. When do we expect the next round of capex, given that now we have given our guidance for ₹2,000 crores by FY '30?

Abhishek Patel

Next round of capex, as we just discussed that plant utilization at Ankleshwar may get filled up by year 2028. Then, that's the reason we are already starting with our future plan, and that is for land acquisition.

Then we'll plan for the next round of capex, that size and scale, we'll decide based on that.

Siddharth Gadekar

Sir. Thank you so much.

Operator

Thank you. The next question comes from the line of Sajal Kapoor from Antifragile Thinking.

Please go ahead.

Sajal Kapoor

Thank you, and congratulations on sustaining strong execution yet again, Naresh. My questions are, first, as the Korea semiconductor facility moves from qualification into commercial ramp-up in next fiscal, should we expect the initial economics to be somewhat lower at the company level, given utilization and startup costs before improving as the volumes scale up?

What would need to happen for the business to reach its targeted steady-state economics? That's my first question.

Thank you. Obviously,

Abhishek Patel

the plant was inaugurated last quarter only, and now it's a time to first get the customer qualification process going. That's the reason for this financial year, we are not giving any tall commitment.

From next financial onward, only it will have a some revenue coming up. Obviously, it will not be a kind of huge revenue or profitability.

It will slowly ramp up. The encouraging things is, we are getting a very good customer inquiry.

We are already started submitting the sample as well as the pilot-scale dispatches, and that's the kind of confidence we can get from that newer geography where we are operating.

Sajal Kapoor

Sure. Helpful.

Second, as CDMO programs move from launch into commercial scale, as you just highlighted, and there can sometimes be an initial inventory build followed by normalization. Given the revised ₹2,000 crores CDMO target by FY '30, how confident are you that this growth will increasingly be diversified across multiple customers and multiple molecules, rather than concentrated in one or two molecules?

If you could just broadly mention how many programs you expect would be material contributors in let's say FY '28?

Abhishek Patel

As we already discussed, that we have multiple products for which the validation batches were already submitted few quarters back, now they have started giving the contribution in terms of commercial revenue. There are 8, 10 products already in pipeline.

That's the reason we are very confident that we will be again able to achieve this second milestone of ₹2,000 crore revenue by FY '30 despite of any industry cycle moving up and down. We are confident that we will achieve those kind of revenue targets.

Sajal Kapoor

Excellent, excellent, sir. Just to clarify the second ₹1,000 crore, 1,000 we will achieve this fiscal, the second ₹1,000 crore will be a lot more diversified and broad-based in terms of molecules and customers, right?

Abhishek Patel

Yes, absolutely right.

Sajal Kapoor

Yeah. Thank you.

That's all.

Operator

Thank you. The next question comes from the line of Nilesh Ghuge from HDFC Securities.

Please go ahead.

Nilesh Ghuge

Thanks for the opportunity. Just one question.

When we are saying ₹1,000 crore of revenue in FY '27, what will be the utilization of our CDMO unit at Ankleshwar? As you mentioned, there is no further capex required till ₹2,000 crore CDMO revenue, what will be the utilization in FY '30 when we achieve CDMO revenue of ₹2,000 crore?

Abhishek Patel

For last quarter, as we said, it was a utilization of 30%. Is when we reach this end of this financial year, it should not be more than, let's say, 40% of the total utilization at Unit 2 Ankleshwar.

For the future, it is difficult to say as of now, because it's a function of multiple things: the volumes, the realization, and the kind of processes.

Nilesh Ghuge

Thanks a lot.

Operator

Thank you. The next question comes from the line of Parth Dalia from Union AMC.

Please go ahead.

Parth Dalia

Yeah. Hi.

Thank you for the opportunity. I just had one question.

This is specifically on darolutamide. Bayer's recent trial showed that the risk of metastasis or death by 58% in high-risk localized prostate cancer.

If this goes into approval, without going into product specifics, how do we think about the volume opportunity if that indication expansions comes through? Directionally, do you have the capacity and contractual framework in place to support that meaningful step-up of volumes over the next 2 to 3 years?

Abhishek Patel

As we are intermediate supplier for this API called darolutamide, and what you're talking about is the formulation market and their indication. At least being at the bottom of the pyramid, we are not able to comment anything on those programs.

This is good for you or the market to understand how the products are going. For us, what we track is what we are getting from the customer, and we should be the beneficiary whatever our customers is gaining in the market.

That is what we see that we are getting a good traction in this product as well as for the next three years, and that is how we are giving the good guidance also.

Parth Dalia

Understand. Got it.

Just extending the question to, let's say, if Bayer for the formulation opportunity, are there upside estimates, do you reckon that?

Abhishek Patel

Sorry, your voice is breaking.

Parth Dalia

Sorry, is it better now?

Abhishek Patel

Yeah.

Parth Dalia

Just a follow-up on that question. Let's say to the innovator's sales, the formulation sales, does this trial lead to a meaningful upgrade in their numbers?

Abhishek Patel

We are not very well placed to comment on whether their formulation market is how much they are going. I think that we will not be able to comment on this.

Parth Dalia

No problem. Thank you so much.

Operator

Thank you. A reminder for all the participants who wish to ask questions may press star and one on their touch-tone telephone.

The next question comes from the line of Rohit Nagraj from 360 ONE Capital. Please go ahead.

Rohit Nagraj

Yeah. Thanks for the opportunity, and congrats on a very strong set of numbers.

Abhishek Patel

Sir,

Rohit Nagraj

first question is on the CDMO front. The ₹2,000 crore guidance for FY '30, in terms of EBITDA margins, would it track the current margins on ₹1,000 crores, or would there be some kind of a dilution that we are expecting?

Thank you.

Abhishek Patel

Largely, it should be in the same range what we are getting for the CDMO business as on date.

Rohit Nagraj

Sure. Second question is on the semiconductor chemicals.

Given that our plant is operational, we are probably sending the validation batches to the South Korean players, are we also engaged with any of the Indian counterparts for validation? If not, are there any immediate plans of serving them?

Thank you.

Abhishek Patel

When you are say Indian, you are referring to Indian semiconductor industry?

Rohit Nagraj

The ecosystem which is getting developed now and which probably will be operational over the next couple of years.

Abhishek Patel

For as of now, whatever we have planned the capacity, that is for Indicam, it is Korean ecosystem and then after outside Korea, geography like Japan and Taiwan. From India, Baba Finechem again, because this ecosystem is yet not that matured, and we have already market available in the export market.

That's the reason we are targeting more of a Korea, Japan, US market only, and that is where we are getting very good traction also. In future, when this ecosystem gets developed, we would be happy to part of that, but as of now, all our capacity as well as the business development largely focus on the export market only.

Rohit Nagraj

Sure. Just one clarification.

In terms of products, once they get validated from our international customers, would it be relatively easier and with a shorter period of timeframe to validate for the Indian counterparts?

Naresh Patel

Let me answer this. See, customer validation is their internal process.

It's not that one big customer approve means that that product can be used by someone else immediately. Because their process and their requirements are different.

The validation process is robust, time-consuming, and it's a long-term. Beauty is that Aequitas and Indicam has a capability to produce very high-end chemicals, and our process is validated, our manufacturing site is validated.

That will help us to consider our Indian customer based on the experience what we have. This is an advantage against the other competitor of ours.

Rohit Nagraj

Perfect, sir. Thanks a lot for answering all the questions, and all the best.

Naresh Patel

Thank you.

Operator

Thank you. The next question comes from the line of Bharat Shah from Bharat Shah Capital Ideas Private Limited.

Please go ahead.

Bharat Shah

Naresh, hearty congratulations to you and Aequitas team.

Naresh Patel

Thank you, sir. Thank you, Bharat.

Bharat Shah

Thank you. Just wanted to have two important views.

Over last three to four years, we made a considerable progress in converting the shape of our farm. From commodity chemicals to the specialty, and from limited relationships to more customer and sticky, long-term relationships.

Our margins, top-line, and capital efficiency all reflect the painstaking work of the past. Now that where we stand, and good part of the capex for the future is under our belt, when you look at next five years, what are your key aspirations?

What are the milestones with which you will like to define Aequitas' or Ami's journey ahead? Secondly, as you stand at these important juncture where we've made a considerable progress, but many more important milestones are lying ahead, what are your key apprehensions or challenges that you perceive?

Naresh Patel

Bharat, thank you, sir, first of all for seeing our journey right when we started in IPO 2021 till today. You are always inspiring and motivating us.

It's a journey which is now giving the fruit of what we had done in last one decade and transforming family company into the structure and professional company, focusing on each area right starting from raw material secure, to process strengthening, to operational efficiency, to manpower upgrading, technology implementation, process improvements, plant atomization, and at the end of the day, customer satisfaction. This is a cumulative effort of our last one decade working, which is giving fruit now.

Regarding what you say, the inspiration for next five years, I have a visibility for the generic, as so many time I said that we have developed a lot of molecule which having an expiry up to 2045. This is how we are working in our research department for generic portfolio strengthening.

Whereas for regulated market, we have a long-term agreement with several customers. That is also helping us to guide for next three years.

We had revised our CDMO target from ₹1,000 crore to ₹2,000 crore based on these new CDMO as well as the old CDMO pipeline. Considering transforming company from pharma to specialty chemicals and the multi-applications for the chemistry.

Now, as I said, when we made it, it was a very primary stage of the battery chemical. Now, it is almost mature and having very strong traction from the customers.

Long-term orders are in pending with us, and now its commercial supply also started. Slowly, slowly it's ramping up, and it's now self-sustained.

The second stage is the semiconductor segment, which is a very important for us, because the beauty of semiconductor business is that everybody cannot be they start today and enter in the market, because it's a very technical-driven, very high-purity chemical production, and a very customer-sticky business. That is helping us by acquiring Baba Finechem has opened our door right from the first day into this ecosystem, and then this ecosystem has teach us how to go for the more pure material, and that's how we put Indicam in South Korea.

Business is teaching us, and we are learning very quickly, and we're implementing also very fast. This experience also helping us when there is a ecosystem start in India.

Today, there is no any demand for semiconductor chemical in India because it's yet not fab is started. Once the fab is start, we are one of very few out of them having all the experience of very high-pure chemical production, and that will help us to immediately cater the market in India as well.

This is how our aim is that, in five years, we should be not known as a pharma company, but as a chemical company having multiple avenues, which can be supply chemical in a different sector.

Bharat Shah

What, in your opinion, are tangible and more qualitative aspirations that you believe Ami Organics is likely to fulfill in the upcoming five-year journey? What possible apprehensions that you carry in your mind, or concerns about potential challenges?

Abhishek Patel

Let me just give some internal matrix at our end. As Naresh shared his vision that he want to create an organization which is not only focused on a pharma chemical, but then we are getting into the multiple chemistry related to battery, related to semiconductor, related to electronics, and there are other multiple areas where we are already working.

For us internally, as tangible, we work on a, let's say, various parameters related to the capital deployment, the ROI, Ultimately, the business has to be self-sustained, standing on its own feet, as well as generating a long-term cash flow and sustainable growth in the future. Like for the battery chemical, we started with two two products.

Then we keep on adding multiple. The third and fourth products are already commercialized, and then it should generate a good cash flow every year.

Then come the sustainability. In terms of sustainability, what we are doing is, we are building a very good healthy customer relationship, by not focusing, as we discussed in last question only, that we are not riding on those $30, $35 kind of pricing wave, rather than we are focusing more on the customer relationship.

This is how we want to convert this business into long-term sustainable cash-generating machine. That is what we are focusing for each and every business what we are targeting.

It's not that we start the business today, we run for 3 years, and then we want to just let it can go down. It has to be sustainable, long-term business only.

That is what we are focusing on each of those businesses.

Bharat Shah

Concerns, if any?

Naresh Patel

Concerns are always there, Bharat, and we have to find out the way out of the concerns. There is a geopolitical issues are there, supply chain, logistics, operational, electricity, water, there are so many constraints are always coming.

We have to find out the way out of that. That is what we are doing day-to-day operation.

For a semiconductor ecosystem is happening in India. If it is delayed, it will be a delayed of implementation in India.

The similar kind of opportunity are it's a huge opportunity for Indian chemical manufacturer in India as well as abroad. Whatever the current mindset of China-free is helping Indian chemical manufacturer on their own capacity to grab the opportunity which is available.

Sometime you grab a lot of opportunity, but you cannot able to grow all because of the competition as well. These all things has to be considered, and this is what we do whenever we enter into segments.

We first analyze everything, whether it is good for us, sustainable for us, long term what will be the situation of the market and all, and then we enter in that segment. This is what we try at most that all the concerns need to be covered, but then if unexpected will come, we have to face that.

Bharat Shah

Sure. Just one last thing.

We've come a long way over last few decades, from Ami to Aequitas, and we built lot of tremendous strengths, even as we still remain relatively rather modest in the size of turnover in business, but rapidly progressing. Would you, Naresh, say that the coming decade will be the most defining, and probably most momentous decade in the kind of future that you visualize, given the opportunity in this space?

Naresh Patel

Absolutely, sir. That is what I said that last last decade was our foundation year, decade where we done lot of seeding.

Now, this seeding, one by one, is giving us the fruit. Now, next decade will be the more important decade for us in terms of getting fruits out of whatever we seeded in last one decade.

Bharat Shah

Sure. Thank you, Naresh.

All the very best, and to the entire Aequitas team for a tremendous transformation of the firm.

Naresh Patel

Thank you, Bharat. Thank you very much.

Happy Diwali.

Operator

Thank you. The next question comes from the line of Pratik Dharmshi from Union Mutual Fund.

Please go ahead.

Pratik Dharmshi

Thanks for giving the opportunity. Many congratulations, Naresh, Abhishek, for a splendid set of numbers.

Just, my question is on the new CDMO projects which you are working on. You mentioned, initially you used to mention around four new projects or CDMOs you're working, and now the number has gone up to 7, 8.

Some color on the therapy would be really appreciated. Apart from, you used to mention around ₹50 crore each sort of a molecule.

Is the run rate similar, or you are expecting some change to it? Is it accelerating, based on now the commercial supplies are starting?

Some more color on it would be really helpful. Thank you.

Abhishek Patel

For CDMO projects, because these are all innovator-driven projects, we are not able to at least share any details related to their product, or their therapeutic segment, or their potential. As we generally say that, for the non-blockbuster product, 50 to ₹100 crore is the kind of range because that's the kind of revenue we can get it as a intermediate player.

As Naresh mentioned, there are some of the very exciting projects already going on, and which has a better revenue possibility, and that gives the confidence that it will be a good growth engine in future also in terms of newer CDMO projects.

Pratik Dharmshi

Got it. Yep, thank you, and all the best.

Abhishek Patel

Thank you.

Operator

Thank you. The next question comes from the line of Meet Vora from JM Financial.

Please go ahead.

Meet Vora

Thanks for the opportunity. Sir, what gives us the confidence to increase our EBITDA margin guidance to 38% to 40% beyond FY '27 on a sustainable basis?

Because this quarter, we have mentioned in our presentation that higher margins are led by gross margin and operating leverage, but will this operating leverage continue going into FY '28 as well, or maybe this upgrade is more to do with higher contribution mix from CDMO?

Abhishek Patel

First thing, at material or the gross level, the margins are always function of the product mix. As you see that just our battery chemical business has just started in this quarter.

That's the reason the large portion of the revenue is coming from the pharma intermediate, and growth is driven by CDMO segment. That is where the high margin is coming, and with the kind of order book we have already in place for the H2 FY '27, we are confident to achieve this ₹1,000 crore mark, which converts into good kind of margin for FY '27.

That's the reason we have raised our margin guidance. Related to operating leverage, obviously, as and when this revenue keeps on increasing within the same premises or the facility, the operating margin has to kick in.

As we just mentioned, the 30% utilization level at Unit 2, and the obviously the very low utilization level at our battery chemical business, the operating margin will keep on adding once those production level scales up. Sir,

Meet Vora

this 38% to 40% EBITDA margin guidance is for FY '27, or this continues for '28?

Abhishek Patel

FY '27.

Meet Vora

Oh, okay. That's it from my side.

Thanks a lot, and best of luck for coming quarters.

Abhishek Patel

Thanks.

Operator

Thank you. The next question comes from the line of Sidharth Negandhi from CWC.

Please go ahead.

Sidharth Negandhi

Hi, congratulations on a great set of numbers. Three questions from my end.

On the pharma intermediates business, you mentioned that CDMO could achieve ₹1,000 crores in FY '27. Could you help us understand how much of that is already in the bag in H1, which is your pharma intermediates business, the innovator and generic split?

That is question one. The second question was on daro.

Can you potentially double the supply from the same facility over the next 2 years, or will you need capex? What is your current utilization, and your wallet share in this?

The third question was on the base business in specialty chemicals. How many more quarters before the commodity chemicals completely go off this business, and most of this will be the battery chemicals and the other specialty chemicals?

These were my three questions.

Abhishek Patel

Related to CDMO, first thing, we are not doing any generic work. We are doing all the CDMO projects with the originator only, these are all originator business, no generic piece over there.

Related to what is in our bag, so, as Naresh already mentioned, this ₹1,000 crore mark guidance for this financial year is based on the customer visibility and the contracts in place, so that is definitely achievable target for us. Your second question related to the kind of split in the business or the market share, we are not able to comment on this, because we only see what originator gives us as a business, and that is what we are guiding.

We are not concerned about the kind of who are who and what who are getting what. Third question related to specialty chemical business, see, we have already started scaling down this old legacy product related to paraben and MS.

It takes some time because right at upfront, we cannot say no to the customer because they also need to develop their alternative vendor and supply line. That's the reason it may take around one, 1.5 year to scale down this business.

MS business, we may continue for some time because there are some good customer already in place, it may take some time beyond 1.5 year also to scale down MS business.

Sidharth Negandhi

Got it. Sorry, just a clarification on the first one.

What I meant is not that CDMO is generic. What I meant is, if I look at the advanced pharma intermediate segment, right, part of that is CDMO business, and part of that is base business.

If you could help us with that split.

Abhishek Patel

Also we are not giving those split also. We see completely as a pharma intermediate business only.

Definitely, it will cross ₹1,000 crore mark, as we already committed. Got it.

For this year.

Sidharth Negandhi

Right. When you say ₹1,000 crore crossing in that business, you mean not for the advanced pharma intermediate segment, only CDMO within that, and outside of the base business?

Abhishek Patel

Yes.

Sidharth Negandhi

Right? Yes, yes,

Abhishek Patel

yes.

Sidharth Negandhi

Got it. Clear.

The second one, while clear on you not looking at wallet share, could you give us some color in terms of daro, if you have to potentially double the daro supply, right, will that need more capex, or where are you in terms of utilization of the facility there? How should one look at that?

Abhishek Patel

As we said, the capacity utilization is 30% only, there is some room available. We are not disclosing anything about whether it is sufficing the production requirement or not.

Sidharth Negandhi

Very clear. Last question on the South Korea facility.

What are the markets that you will target for supply from this facility? Would it be Korea, Japan primarily?

Are you looking at some cell manufacturers in India or Southeast Asia also? How should one think of that business?

Abhishek Patel

For Korea, it's a semiconductor business, our target customer photoresists and the fab industry and a semiconductor consumption industry. It's not a kind of cell manufacturer, and largely because those are based in Korea and Japan, these are our potential customer market.

Sidharth Negandhi

Understood. Sorry, got it.

Yeah. Thank you very much, and wish you all the best.

Operator

Thank you. The next question comes from the line of Juhi Kumari from Narnolia Financial Services Limited.

Please go ahead.

Juhi Kumari

Thanks for the opportunity. Congratulations on the strong set of numbers.

My first question is regarding the battery electrolytes additives production. It was expected to start in second quarter FY '27.

Just wanted to know that has the commercial supply began, and what was the revenue contribution during the current quarter?

Abhishek Patel

We have already started commercials, supply for VC and FEC as well as the third product also, ahead of the time, and the fourth product, the validation batches are already, been supplied, at a from a pilot scale. Revenue contribution, we are not disclosing.

It is just a start, and ramp-up is expected in next 2 to 3 quarters.

Juhi Kumari

Sure, thanks. My second question is regarding what portion of the remaining ₹349 million specialty chemical revenue is still compromised of commodity chemicals scheduled for exit, and once this phasing out is complete and BFC normalizes, what is the steady-state quarterly revenue expectation from specialty chemicals?

Abhishek Patel

For specialty chemical, we are not giving any split between old traditional specialty chemical product or the battery chemical, but it will remain in this territory, and with a ramp-up from the battery chemical business. Overall, there will be a growth as against what number we have reported last financial year.

Juhi Kumari

We expect this to remain in a state where it has been in the first half FY '27?

Abhishek Patel

Yes.

Juhi Kumari

Okay. Just one last question about the gross margin expansion that has expanded significantly to 62.1% this quarter.

How much of this expansion came from raw material prices softening versus a structural shift in product mix towards higher margin?

Abhishek Patel

Gross margin expansion is a function of both: product mix, as well as the raw materials. In total, we cannot bifurcate between raw material price escalation or the kind of product mix.

It's a function of both.

Juhi Kumari

Is there any leverage that we have got from raw material price softening this quarter?

Abhishek Patel

No, we are not seeing that raw material price has softened in the quarter. In fact, that is definitely not the case.

Juhi Kumari

Okay. Thanks for the answer, and all the best for the coming quarters.

Operator

Okay. The next question comes from the line of Basant Bansal from NBG Investments.

Please go ahead.

Basant Bansal

Good evening Abhishek. My question to you is that, in the first half, our pharma revenue is ₹695 crore.

Can you tell me out of ₹695 crore, how much is CDMO?

Abhishek Patel

₹95 crore? I didn't understand.

Basant Bansal

₹695 crore.

Abhishek Patel

Sorry?

Basant Bansal

₹695 crore is your first half revenue from pharma vertical. So, 1 minute, wait, sir.

Pharma, no. Number.

Abhishek Patel

Sorry, your voice is little echoing. You are saying out of 6, 95, ₹695

Basant Bansal

No. I am saying, I am seeing your slide number six wherein the revenue from pharma intermediate vertical is shown as ₹695 crore.

I want to know out of this, how much is CDMO?

Abhishek Patel

Okay. Oh, sorry, we are not disclosing those split in subsegment of this pharma intermediate business.

Basant Bansal

Okay. Can you tell me in percentage terms, if possible?

Abhishek Patel

No, again, it's the same thing, sir. Same thing.

Basant Bansal

Achha. No problem.

Thank you.

Operator

Thank you. Ladies and gentlemen, we will take this as the last question for today.

I now hand over to the management for closing comments. Over to you, sir.

Abhishek Patel

Thank you, Equirus team, for hosting our conference call. We appreciate everyone's questions and hope we have addressed most of your queries.

If we missed any of your questions, please reach out to our investor relations team, and we will get back to you promptly. Once again, thank you very much, and happy festivals.

Operator

Thank you. On behalf of Equirus Securities Private Limited, that concludes this conference.

Thank you for joining us, and you may now disconnect your lines.